OncXerna Therapeutics Announces New Xerna™ TME Panel Biomarker Data from Retrospective Analysis of Results from a Randomized Phase 2 Trial Evaluating Anti-PD-1 Maintenance Therapy in Esophagogastric Adenocarcinoma at the ESMO Congress 2022

Better 24-month survival was achieved when durvalumab was used for maintenance compared to surveillance in esophagogastric adenocarcinoma patients with “high” Xerna TME Panel immune scores, despite these patients having a poorer prognosis Data suggest the Xerna TME...